Ovid Therapeutics (OVID) Revenue (2020 - 2026)

Ovid Therapeutics (OVID) has reported Revenue for 7 consecutive years, with $733000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue fell 88.31% year-over-year to $733000.0; the trailing twelve-month figure through Jun 2026 stood at $1.6 million (down 76.2% YoY), and the FY2025 full-year result was $7.3 million, up 1181.27% from the prior year.
• Revenue rose to $733000.0 in Q2 2026 per OVID's latest filing, from $718000.0 in the prior quarter.
• Across five years, Revenue topped out at $6.3 million in Q2 2025 and bottomed at $11102.0 in Q3 2022.
• Historically, Revenue has averaged $652859.2 across 5 years, with a median of $137000.0 in 2023.
• The sharpest annual moves came in 2022 and 2025: Revenue plunged 99.31% in 2022, then jumped 3611.24% in 2025.
• Over 5 years, Revenue stood at $46280.0 in 2022, then soared by 206.83% to $142000.0 in 2023, then plunged by 46.48% to $76000.0 in 2024, then soared by 844.74% to $718000.0 in 2025, then climbed by 2.09% to $733000.0 in 2026.
• According to Business Quant data, Revenue over the past three periods registered $733000.0, $718000.0, and $132000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.